Targeting CD47/SIRPα represents a novel approach to enhance anti-tumor immunity by augmenting or reactivating critical tumor clearance mechanisms, as a key immune checkpoint in different cancers similar to that of the PD-1/PD-L1 checkpoint for solid tumors. The gene discussed is CD47; the disease is cancer.